# The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

> **NCT05696392** · PHASE4 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 47 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** ruxolitinib cream

## Key facts

- **NCT ID:** NCT05696392
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-16
- **Primary completion:** 2025-01-22
- **Final completion:** 2025-01-22
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** The study was terminated due to lack of enrollment.
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05696392

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05696392, "The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05696392. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*